Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis.

From:
Department for International Development
Published
1 January 2011
Document Type:
Journal Article
Theme:
Health
Authors:
Nuermberger, E.L., Ahmad, Z., Minkowski, A., Peloquin, C.A., Williams, K.N., Mdluli, K.E., Grosset, J.H.

Abstract

DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.

Citation

Antimicrobial Agents and Chemotherapy (2011) 55 (4) 1781-1783 [doi:10.1128/AAC.01514-10]

Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis.

Published 1 January 2011
Contents